Obesity is a chronic, relapsing disease with a multifactorial etiology. Over the past five years, obesity medicine has entered a new era with the advent of novel, game-changing pharmacotherapies that achieve weight loss exceeding 15-20%. Beyond weight loss, these powerful therapies offer additional benefits, such as cardiovascular improvements. These novel agents, such as GLP-1 receptor agonists (GLP-1RAs), work by reducing appetite, slowing gastric emptying, and increasing feelings of fullness….
